Industry
Medical - Devices
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Loading...
Open
1.00
Mkt cap
56M
Volume
410K
High
1.04
P/E Ratio
-0.86
52-wk high
1.58
Low
0.98
Div yield
N/A
52-wk low
0.63
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 12:08 pm
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 12:17 pm
Portfolio Pulse from Benzinga Newsdesk
July 23, 2024 | 12:04 pm
Portfolio Pulse from Benzinga Newsdesk
July 02, 2024 | 12:06 pm
Portfolio Pulse from Benzinga Newsdesk
July 02, 2024 | 11:56 am
Portfolio Pulse from Benzinga Newsdesk
June 12, 2024 | 12:11 pm
Portfolio Pulse from Benzinga Newsdesk
June 06, 2024 | 5:14 pm
Portfolio Pulse from Benzinga Newsdesk
May 15, 2024 | 12:25 pm
Portfolio Pulse from Benzinga Newsdesk
May 13, 2024 | 3:50 pm
Portfolio Pulse from Benzinga Newsdesk
May 13, 2024 | 12:08 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.